By: Kristopher A. May, OD, FAAO; Leslie O’Dell, OD, FAAO; Deborah Ristvedt, DO; Justin Schweitzer, OD, FAAO
This course features bonus case material. View it here
Supported by an unrestricted educational grant from Sight Sciences.
1. Describe the impact of resistance in different outflow pathways on glaucoma patient outcomes
2. Identify the efficacy levels, short-term complication rates and long-term tissue removal risks of various glaucoma surgical procedures
There is no credit associated with this course.
Christopher May, OD
Moderator
Coldwater Vision Center
Coldwater, MS
Deborah Ristvedt, DO
Vance Thompson Vision
Alexandria, MN
Leslie O’Dell, OD
Clinical Director of Medical Optometry America
York, PA
Justin Schweitzer, OD
Vance Thompson Vision
Sioux Falls, SD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Kristopher May, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Sight Sciences. Speaker’s Bureau: Alcon, Bausch + Lomb, and Sight Sciences.
Leslie O’Dell, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie and Sight Sciences.
Deborah Ristvedt, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences. Grant/Research Support: Allergan. Speaker’s Bureau: Alcon, and Glaukos.
Justin Schweitzer, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompe, EyePoint, Horizon, Ocular Therapeutix, and Reichert. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceuticals. Share/Stockholder: Equinox.
The Evolve Medical Education or The Fundingsland Group staff and planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Sight Sciences.
By: Kristopher A. May, OD, FAAO; Leslie O’Dell, OD, FAAO; Deborah Ristvedt, DO; Justin Schweitzer, OD, FAAO